Press coverage about Aquinox Pharmaceuticals (NASDAQ:AQXP) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aquinox Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.6679132215237 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
A number of brokerages recently issued reports on AQXP. Zacks Investment Research downgraded Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. Canaccord Genuity set a $22.00 price objective on Aquinox Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 19th. Needham & Company LLC reiterated a “buy” rating and set a $25.00 price objective on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $28.00 price objective on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. Aquinox Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $22.00.
Aquinox Pharmaceuticals (NASDAQ AQXP) traded down $0.14 during mid-day trading on Monday, reaching $11.51. The company’s stock had a trading volume of 29,100 shares, compared to its average volume of 68,500. Aquinox Pharmaceuticals has a 1-year low of $10.02 and a 1-year high of $19.97. The company has a market cap of $270.08, a P/E ratio of -5.96 and a beta of -16.96.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.12. sell-side analysts expect that Aquinox Pharmaceuticals will post -2.08 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Aquinox Pharmaceuticals (AQXP) Receives Daily News Sentiment Score of 0.12” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/01/15/aquinox-pharmaceuticals-aqxp-receives-daily-news-impact-score-of-0-12.html.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.